Diagnostics and Prognostication of Myelodysplastic Syndromes

Overview

Journal Ann Lab Med

Specialty Pathology

Date 2017 Aug 26

PMID 28840983

Citations 5

Authors

Gina Zini

Affiliations

Soon will be listed here.

Abstract

MDS are a heterogeneous and complex group of clonal hematological neoplasms arising from a hematopoietic stem cell, and characterized by ineffective hematopoiesis, resulting in increased apoptosis in the bone marrow and peripheral cytopenia, which involves one or more lineages. Epigenetic changes are reported as 'founder' mutations in the case of MDS. Its incidence in the general population has been reported as five new MDS diagnoses per 100,000 people. It affects men more frequently than it does women, and its incidence increases with age. The diagnostic classification, now in use, is the one of the World Health Organization, revised in August 2016. It recognizes six distinct entities in addition to a provisional entity of childhood. In most of the cases, diagnosis is based on the morphologic quantitative and qualitative evaluation of the peripheral blood and bone marrow using basic hematological techniques. Bone marrow biopsy and flow cytometric immunophenotyping also offer support for further diagnostic elucidation, while cytogenetics and molecular genetics are presently fully integrated into prognostication, treatment processes, and decision-making.

Citing Articles

Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes.

Lee N, Jeong S, Park M, Song W Sci Rep. 2022; 12(1):18677.

PMID: 36333407 PMC: 9636228. DOI: 10.1038/s41598-022-21887-w.

Myelodysplastic syndromes and overlap syndromes.

Chang Y Blood Res. 2021; 56(S1):S51-S64.

PMID: 33935036 PMC: 8094000. DOI: 10.5045/br.2021.2021010.

KIR3DL1 and HLA-Bw4 Interaction Showed a Favorable Role in Patients with Myelodysplastic Syndromes in Chinese Southern Han.

Zhen J, Cai S, Chen Y, Yang Z, Zhuo J, Deng Z Biomed Res Int. 2020; 2020:6215435.

PMID: 32420357 PMC: 7210520. DOI: 10.1155/2020/6215435.

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.

Park S, Kelaidi C, Meunier M, Casadevall N, Gerds A, Platzbecker U Ann Hematol. 2019; 99(1):7-19.

PMID: 31650290 PMC: 6944671. DOI: 10.1007/s00277-019-03799-4.

Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.

Tataranni T, Mazzoccoli C, Agriesti F, De Luca L, Laurenzana I, Simeon V Stem Cell Res Ther. 2019; 10(1):171.

PMID: 31196186 PMC: 6567456. DOI: 10.1186/s13287-019-1293-y.

References

Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

Lim E, Cembrowski G, Cembrowski M, Clarke G . Race-specific WBC and neutrophil count reference intervals. Int J Lab Hematol. 2010; 32(6 Pt 2):590-7. DOI: 10.1111/j.1751-553X.2010.01223.x. View

Goasguen J, Bennett J, Bain B, Brunning R, Vallespi M, Tomonaga M . Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2014; 38(4):447-53. DOI: 10.1016/j.leukres.2013.12.020. View

Paydas S . Young age MDS: differences between Western and Eastern countries. Leuk Res. 2005; 30(3):362. DOI: 10.1016/j.leukres.2005.07.005. View

Itzykson R, Fenaux P . Epigenetics of myelodysplastic syndromes. Leukemia. 2013; 28(3):497-506. DOI: 10.1038/leu.2013.343. View

Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G . Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-506. PMC: 3159042. DOI: 10.1056/NEJMoa1013343. View

Bain B . The bone marrow aspirate of healthy subjects. Br J Haematol. 1996; 94(1):206-9. DOI: 10.1046/j.1365-2141.1996.d01-1786.x. View

Steensma D, Bejar R, Jaiswal S, Lindsley R, Sekeres M, Hasserjian R . Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1):9-16. PMC: 4624443. DOI: 10.1182/blood-2015-03-631747. View

Patnaik M, Hanson C, Sulai N, Hodnefield J, Knudson R, Ketterling R . Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674-7. DOI: 10.1182/blood-2012-03-415356. View

10.

Lewinsohn M, Brown A, Weinel L, Phung C, Rafidi G, Lee M . Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2015; 127(8):1017-23. PMC: 4968341. DOI: 10.1182/blood-2015-10-676098. View

11.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

12.

Hahn C, Chong C, Carmichael C, Wilkins E, Brautigan P, Li X . Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011; 43(10):1012-7. PMC: 3184204. DOI: 10.1038/ng.913. View

13.

Charafeddine K, Ibrahim G, Mahfouz R, Zaatari G, Salem Z . Chronic lymphocytic leukemia associated with myelodysplastic syndrome with ring sideroblasts. South Med J. 2010; 103(8):823-7. DOI: 10.1097/SMJ.0b013e3181e6d2b4. View

14.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

15.

Dinmohamed A, Visser O, van Norden Y, Huijgens P, Sonneveld P, van de Loosdrecht A . Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer. 2014; 50(5):1004-12. DOI: 10.1016/j.ejca.2013.12.002. View

16.

Niemeyer C, Baumann I . Myelodysplastic syndrome in children and adolescents. Semin Hematol. 2008; 45(1):60-70. DOI: 10.1053/j.seminhematol.2007.10.006. View

17.

Bannon S, DiNardo C . Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci. 2016; 17(6). PMC: 4926372. DOI: 10.3390/ijms17060838. View

18.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

19.

Malcovati L, Della Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E . Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603. DOI: 10.1200/JCO.2005.01.7038. View

20.

Bueso-Ramos C, Kanagal-Shamanna R, Routbort M, Hanson C . Therapy-Related Myeloid Neoplasms. Am J Clin Pathol. 2015; 144(2):207-18. DOI: 10.1309/AJCPU1JO2LYTWUAV. View